Priming mesenchymal stem cells boosts stem cell therapy to treat myocardial infarction

Journal of Cellular and Molecular Medicine

Volumn 17, Issue 5, 2013, Pages 617-625

  Carvalho, Juliana L ^a   Braga, Vinicius B A ^a   Melo, Marcos B ^a   Campos, Ana Carolina D A ^a   Oliveira, Maira S ^a   Gomes, Dawidson A ^a   Ferreira, Anderson J ^a   Santos, Robson A S ^a   Goes, Alfredo M ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Adipose tissue stem cells; Cell therapy; Connexin 43; Mesenchymal stem cells; Myocardial infarction

Indexed keywords

ACTININ; CONNEXIN 43; ENHANCED GREEN FLUORESCENT PROTEIN; GREEN FLUORESCENT PROTEIN;

ANIMAL; ARTICLE; CELL DIFFERENTIATION; CELL SEPARATION; CYTOLOGY; ECHOCARDIOGRAPHY; HEART FUNCTION TEST; HEART INFARCTION; HEART MUSCLE CELL; IMMUNOBLOTTING; LEWIS RAT; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; RAT; SARCOMERE;

ACTININ; ANIMALS; CELL DIFFERENTIATION; CELL SEPARATION; CONNEXIN 43; ECHOCARDIOGRAPHY; GREEN FLUORESCENT PROTEINS; HEART FUNCTION TESTS; IMMUNOBLOTTING; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; RATS; RATS, INBRED LEW; SARCOMERES;

RATTUS;

EID: 84878372480     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12036     Document Type: Article

References (29)

1. World Health Organization. Factsheet number 371, September 2011. http://www.who.int/mediacentre/factsheets/fs317/en/index.html, accessed in June 2012.
2. Beltrami AP, Barlucchi L, Torella D, et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell. 2003; 114: 763-76.
3. Laflamme MA, Murry CE. Regenerating the heart. Nat Biotechnol. 2005; 23: 845-56.
4. He Q, Trindade PT, Stumm M, et al. Fate of undifferentiated mouse embryonic stem cells within the rat heart: role of myocardial infarction and immune suppression. J Cell Mol Med. 2009; 13: 188-201.
5. Blin G, Nury D, Stefanovic S, et al. A purified population of multipotent cardiovascular progenitors derived from primate pluripotent stem cells engrafts in postmyocardial infarcted nonhuman primates. J Clin Invest. 2010; 120: 1125-39.
6. Kollaros N, Theodorakos A, Manginas A, et al. Bone marrow stem cell adherence into old anterior myocardial infarction: a scintigraphic study using Tl-201 and Tc-99m-HMPAO. Ann Nucl Med. 2012; 26: 228-33.
7. Copland IB. Mesenchymal stromal cells for cardiovascular disease. J Cardiovasc Dis Res. 2011; 2: 3-13.
8. Williams AR, Hare JM. Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res. 2011; 109: 923-40.
9. Wan Safwani WK, Makpol S, Sathapan S, et al. 5-Azacytidine is insufficient for cardiogenesis in human adipose-derived stem cells. J Negat Results Biomed. 2012; 11:3.
10. Rose RA, Jiang H, Wang X, et al. Bone marrow-derived mesenchymal stromal cells express cardiac-specific markers, retain the stromal phenotype, and do not become functional cardiomyocytes in vitro. Stem Cells. 2008; 26: 2884-92.
11. Leistner DM, Fischer-Rasokat U, Honold J, et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI): final 5-year results suggest long-term safety and efficacy. Clin Res Cardiol. 2011; 100: 925-34.
12. Dill T, Schächinger V, Rolf A, et al. Intracoronary administration of bone marrow-derived progenitor cells improves left ventricular function in patients at risk for adverse remodeling after acute ST-segment elevation myocardial infarction: results of the Reinfusion of Enriched Progenitor cells And Infarct Remodeling in Acute Myocardial Infarction study (REPAIR-AMI) cardiac magnetic resonance imaging substudy. Am Heart J. 2009; 157: 541-7.
13. Meyer GP, Wollert KC, Lotz J, et al. Intracoronary bone marrow cell transfer after myocardial infarction. Eighteen months' follow-up data from the randomized, controlled BOOST (Bone marrow transfer to enhance ST-elevation infarct regeneration) trial. Circulation. 2006; 113: 1287-94.
14. Menasché P, Alfieri O, Janssens S, et al. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation. 2008; 117: 1189-200.
15. Zuk PA, Zhu M, Ashjian P, et al. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell. 2002; 13: 4279-95.
16. Neuhuber B, Gallo G, Howard L, et al. Reevaluation of in vitro differentiation protocols for bone marrow stromal cells: disruption of actin cytoskeleton induces rapid morphological changes and mimics neuronal phenotype. J Neurosci Res. 2004; 77: 192-204.
17. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999; 284: 143-8.
18. Planat-Bénard V, Menard C, André M, et al. Spontaneous cardiomyocyte differentiation from adipose tissue stroma cells. Circ Res. 2004; 94: 223-9.
19. Marques FD, Ferreira AJ, Sinisterra RD, et al. An oral formulation of angiotensin-(1-7) produces cardioprotective effects in infarcted and isoproterenol-treated rats. Hypertension. 2011; 57: 477-83.
20. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotentmesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006; 8: 315-7.
21. Mese G, Richard G, White TW. Gap junctions: basic structure and function. J Invest Dermatol. 2007; 127: 2516-24.
22. Assis AC, Carvalho JL, Jacoby BA, et al. Time-dependent migration of systemically delivered bone marrow mesenchymal stem cells to the infarcted heart. Cell Transplant. 2010; 19: 219-30.
23. Polchert D, Sobinsky J, Douglas G, et al. IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol. 2008; 38: 1745-55.
24. Waterman RS, Tomchuck SL, Henkle SL, et al. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS ONE. 2010; 5: e10088.
25. Haider HK, Lei Y, Ashraf M. MyoCell, a cell-based, autologous skeletal myoblast therapy for the treatment of cardiovascular diseases. Curr Opin Mol Ther. 2008; 10: 611-21.
26. Lu G, Haider HKh, Porollo A, et al. Mitochondria-specific transgenic overexpression of connexin-43 simulates preconditioning-induced cytoprotection of stem cells. Cardiovasc Res. 2010; 88: 277-86.
27. Giardina SF, Mikami M, Goubaeva F, et al. Connexin-43 confers resistance to hydrogen peroxide-mediated apoptosis. Biochem Biophys Res Commun. 2007; 362: 747-52.
28. Nakase T, Fushiki S, Sohl G, et al. Neuroprotective role of astrocytic gap junctions in ischemic stroke. Cell Commun Adhes. 2003; 10: 413-7.
29. Steinhauser ML, Lee RT. Regeneration of the heart. EMBO Mol Med. 2011; 3: 701-12.